As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...
Looking for a reliable flashlight that will stand up to daily use? You might consider picking up a model that's actually ...
Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has ...
ARV-102 is an oral, brain-penetrant investigational PROTAC designed to degrade LRRK2, which is a large, multidomain scaffolding kinase. Increased activity, scaffolding, and expression of LRRK2 have ...
Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...
University of Pittsburgh School of Medicine scientists have developed drug candidates that early tests suggest could reverse HIV’s ability to escape detection by the immune system. The team’s research ...
The oncology market for PROTACs is projected to reach $3.7 billion by 2030, even though there are no FDA approved therapies currently. Protein homeostasis is critical for physiology of cell and their ...
A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...
New York, USA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight DelveInsight’s PROTAC Market Insights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback